VCT220
1 paper3 findings
- 1 lab in 1 country
- Human trial1
Outcomes
3Blood pressure
downin humans1
1 study
Blood pressure
downin humans1
VCT220 decreases blood pressure in humans.
Human trialoverweight or obesity16 weeksn = 250
Signal transduction and targeted therapy14 Aug 2026
HbA1c
downin humans1
1 study
HbA1c
downin humans1
VCT220 decreases HbA1c in humans.
Human trialoverweight or obesity16 weeksn = 250
Signal transduction and targeted therapy14 Aug 2026
Body weight
downin humans1
1 study
Body weight
downin humans1
VCT220 decreases body weight in humans (-5.75% to -9.73% vs -1.61%).
Human trialoverweight or obesity80 mg, 120 mg, or 160 mg16 weeksn = 250
Signal transduction and targeted therapy14 Aug 2026
Latest
1 in 12 monthsSignal Transduction and Targeted Therapy
Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial
Randomised trial in 250 peopleObesity